Cat. No. | Product name | CAS No. |
DCC2642 |
icec0943
Novel selective inhibitor of CDK7 |
|
DCC2643 |
Ici-185282
Potent thromboxane receptor antagonist |
106393-80-0 |
DCC2644 |
Ici-56780
Antimalarial agent, displaying blood schizonticidal activity against P.berghei |
28130-28-1 |
DCC2645 |
Iclaprim
Novel selective bacterial dihydrofolate inhibitor, antibiotic, actively against Gram positive organisms |
192314-93-5 |
DCC2646 |
Icl-ccic-0019
Novel potent and selective inhibitor of choline kinase alpha (CHKA) |
936498-64-5 |
DCC2647 |
Icl-sirt078
Novel highly selective, substrate-competitive SIRT2 inhibitor, displaying a significant neuroprotective effect in a lactacystin-induced model of Parkinsonian neuronal cell death in the N27 cell line |
1060430-64-9 |
DCC2648 |
Icpd62
Novel inhibitor of heat shock protein 90 (Hsp90), demonstrating anticancer activity against colorectal, osteosarcoma and cervical cancer cell lines |
|
DCC2649 |
Icrf-193
DNA topoisomerase II inhibitor |
21416-88-6 |
DCC2650 |
Ict2700
Potent cytotoxin selectively by CYP1A1 as a tumor-selective treatment for human bladder cancers |
|
DCC2651 |
Id110460001
Novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist |
1110883-26-5 |
DCC2652 |
Id110460002
Novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist |
1172882-21-1 |
DCC2653 |
Id110460003
Novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist |
1428367-46-7 |
DCC2654 |
idaverine
M1 and M2 Antagonist |
100927-13-7 |
DCC2655 |
Ide-in-37 Tfa Salt
Novel highly potent substrate-selective inhibitor of insulin-degrading enzyme (IDE), blocking insulin binding while allowing glucagon cleavage, even at saturating inhibitor concentrations |
|
DCC2656 |
Ide-in-63 Tfa Salt
Novel highly potent substrate-selective inhibitor of insulin-degrading enzyme (IDE), blocking insulin binding while allowing glucagon cleavage, even at saturating inhibitor concentrations |
|
DCC2657 |
Idh2 Inhibitor
Novel isocitrate dehydrogenase 2 (IDH2) mutants inhibitor for the treatment of cancer |
|
DCC2658 |
Idi-3783
Novel mutant-selective Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor |
901031-43-4 |
DCC2659 |
Ido1/2 Inhibitor 4t
The first inhibitor targeting both IDO1/2 that has excellent in vitro inhibitory activity (IDO1 IC50 = 28 nM and IDO2 IC50 = 144 nM) |
|
DCC2660 |
idoxifene
Selective ER modulator (SERM) |
116057-75-1 |
DCC2661 |
Idr-0081053
Novel bactericidal agent against M. tuberculosis under acidic conditions, being effective at sterilizing cultures in a concentration-dependent fashion at the highest concentrations |
|
DCC2662 |
Idr-0099118
Novel concentration dependent bactericidal agent against M. tuberculosis, being markedly more efficient at killing M. tuberculosis under acidic conditions |
693804-72-7 |
DCC2663 |
Idr-1002
Innate Defence Regulator Peptide, Enhancing Monocyte Migration and Adhesion on Fibronectin |